Predictors and Management of Loss of Response to Vedolizumab in Inflammatory Bowel Disease

BACKGROUND: We quantified loss of response (LOR) to vedolizumab (VDZ) in clinical practice and assessed the effectiveness of VDZ dose intensification for managing LOR. METHODS: Retrospective review (May 2014–December 2016) of a prospectively maintained inflammatory bowel disease (IBD) registry. Kapl...

Volledige beschrijving

Bewaard in:
Bibliografische gegevens
Gepubliceerd in:Inflamm Bowel Dis
Hoofdauteurs: Shmidt, Eugenia, Kochhar, Gursimran, Hartke, Justin, Chilukuri, Prianka, Meserve, Joseph, Chaudrey, Khadija, Koliani-Pace, Jenna L, Hirten, Robert, Faleck, David, Barocas, Morris, Luo, Michelle, Lasch, Karen, Boland, Brigid S, Singh, Siddharth, Vande Casteele, Niels, Sagi, Sashidhar Varma, Fischer, Monika, Chang, Shannon, Bohm, Matthew, Lukin, Dana, Sultan, Keith, Swaminath, Arun, Hudesman, David, Gupta, Nitin, Kane, Sunanda, Loftus, Edward V, Sandborn, William J, Siegel, Corey A, Sands, Bruce E, Colombel, Jean-Frederic, Shen, Bo, Dulai, Parambir S
Formaat: Artigo
Taal:Inglês
Gepubliceerd in: Oxford University Press 2018
Onderwerpen:
Original Clinical Articles
Online toegang:https://ncbi.nlm.nih.gov/pmc/articles/PMC6693035/
https://ncbi.nlm.nih.gov/pubmed/29788240
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/ibd/izy171
Tags: Voeg label toe
Geen labels, Wees de eerste die dit record labelt!

Gelijkaardige items